Filter posts

2013 Novel Drug Approvals

The FDA approved 24 novel drugs last year by our count, in line with average …

More than a Quarter of 2013 US-Based Biotech IPOs Call California Home

And of those 39 US-based biotech companies, five of them are from San Diego, highlighting …

BIO CEO Company Snapshot: Conatus Pharmaceuticals

The Company Snapshots have returned for our next One-on-One Partnering event, the BIO CEO & …

#BIOBuyside Twitter Chat: What Do Biotech Investors Expect in 2014?

Is 2014 a good time to invest in biotech? How many biotech IPOs will there …

What’s In Store for Biotechs at this Year’s CEO & Investor Conference

In just a few weeks, industry leaders will gather in New York for one of …

Bioscience’s Bright Spots

According to Business Xpansion Journal, biotech is still big business and partnerships lead to profit. And BIO …

Couldn’t Make it to San Francisco This Week?

Me neither, so here is what I am reading for updates about the 32nd Annual JPMorgan Healthcare …

BIO White Paper Highlights Key Industry Legislation and its Impact on the Industry

Innovative biotech companies at all stages of the development process are working toward next generation …

What’s Behind the Biotech IPO Boom?

Everyone knows that it’s been a knock-out year for the biotech sector in the public …

The Value of Partnering Continues to be a Draw for BIO Events

Last month’s BIO Convention in China saw 700 partnering meetings between executives from biotechnology, pharmaceutical companies and investment …